ArticleBMC cancer2025
Characteristics and trend analysis of cancer mortality among residents of the Xizang autonomous region, 2014-2023.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Xizang Autonomous Region, located in China's southwestern frontier with an average elevation of 4000 m, faces socioeconomic development challenges influenced by its natural environment and regional disparities. Previous studies have indicated that cancer ranks as the fourth leading cause of death among permanent residents in Xizang. However, there is a paucity of research on the trends and characteristics of cancer mortality in this region. This study aims to analyze mortality data from Xizang between 2014 and 2023 to elucidate the characteristics and trends of cancer deaths and to provide a foundation for developing effective cancer prevention and treatment strategies.
methodsMortality data for cancer patients from 2014 to 2023 were extracted from the Death Information Registration and Management System of the Chinese Center for Disease Control and Prevention (CDC). The population data for Xizang were obtained from the Basic Information System of the Chinese CDC. Crude and age-standardized mortality rates were computed via SPSS software, and joinpoint regression models were employed to estimate the average annual percent change (AAPC) in mortality trends.
resultsBetween 2014 and 2023, the crude mortality rate (CMR) for cancer increased from 31.38 per 100,000 to 49.37 per 100,000, whereas the age-standardized mortality rate (ASMR) rose from 50.15 per 100,000 to 66.42 per 100,000, with annual increases of 4.59% and 2.12%, respectively. The leading causes of cancer death are liver cancer, stomach cancer, lung cancer, esophageal cancer, and cervical cancer.
conclusionCancer mortality in Xizang is increasing, with higher rates in men than in women, although the rate of increase is faster in women. Mortality rates increase with age, predominantly affecting middle-aged and elderly populations. Liver and stomach cancers are the primary contributors to cancer mortality. Given the severe cancer control situation, comprehensive prevention strategies and early diagnosis and treatment for high-risk populations are crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.